CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 54 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2019. The put-call ratio across all filers is 0.01 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,949 | -32.4% | 143,463 | -16.7% | 0.00% | -50.0% |
Q2 2023 | $5,841 | +48.9% | 172,134 | +57.9% | 0.00% | +100.0% |
Q1 2023 | $3,922 | -24.4% | 109,024 | -6.4% | 0.00% | 0.0% |
Q4 2022 | $5,191 | -99.9% | 116,471 | -19.4% | 0.00% | -50.0% |
Q3 2022 | $4,064,000 | +55.2% | 144,587 | +48.9% | 0.00% | +100.0% |
Q2 2022 | $2,618,000 | -62.8% | 97,087 | -53.0% | 0.00% | -66.7% |
Q1 2022 | $7,041,000 | -34.9% | 206,700 | -26.2% | 0.01% | +200.0% |
Q4 2021 | $10,816,000 | +403.8% | 279,904 | +603.8% | 0.00% | +100.0% |
Q3 2021 | $2,147,000 | +194.1% | 39,768 | +82.2% | 0.00% | – |
Q2 2021 | $730,000 | -36.0% | 21,825 | -60.5% | 0.00% | -100.0% |
Q1 2021 | $1,140,000 | +12566.7% | 55,299 | +10959.8% | 0.00% | – |
Q4 2020 | $9,000 | -30.8% | 500 | -42.3% | 0.00% | – |
Q3 2020 | $13,000 | – | 866 | +43200.0% | 0.00% | – |
Q2 2020 | $0 | – | 2 | -92.3% | 0.00% | – |
Q3 2019 | $0 | -100.0% | 26 | -99.3% | 0.00% | – |
Q2 2019 | $10,000 | -77.8% | 3,926 | -57.0% | 0.00% | – |
Q1 2019 | $45,000 | – | 9,126 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |